Have a feature idea you'd love to see implemented?
Let us know!
KROS Keros Therapeutics Inc
Price (delayed)
$53.84
Market cap
$2.18B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.21
Enterprise value
$1.67B
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros
Highlights
The revenue has surged by 140% since the previous quarter
The gross profit has soared by 140% from the previous quarter
The quick ratio has grown by 6% YoY but it has contracted by 4.2% from the previous quarter
The debt has grown by 38% from the previous quarter and by 35% YoY
The company's net income fell by 27% YoY and by 8% QoQ
Key stats
What are the main financial stats of KROS
Market
Valuations
Earnings
Shares outstanding
40.51M
Market cap
$2.18B
Enterprise value
$1.67B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.79
Price to sales (P/S)
3,108.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,562.32
Revenue
$651,000
EBIT
-$181.57M
EBITDA
-$178.84M
Free cash flow
-$142.5M
Per share
Balance sheet
Liquidity
EPS
-$5.21
Free cash flow per share
-$3.79
Book value per share
$14.2
Revenue per share
$0.02
TBVPS
$15.41
Total assets
$579.27M
Total liabilities
$46.44M
Debt
$19.29M
Equity
$532.84M
Working capital
$523.04M
Debt to equity
0.04
Current ratio
19.03
Quick ratio
18.36
Net debt/EBITDA
2.87
Margins
Efficiency
Dividend
EBITDA margin
-27,472%
Gross margin
100%
Net margin
-27,890.9%
Operating margin
-31,341.6%
Return on assets
-38.4%
Return on equity
-41.7%
Return on invested capital
-506.2%
Return on capital employed
-33%
Return on sales
-27,890.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KROS stock price
How has the Keros Therapeutics stock price performed over time
Intraday
-0.55%
1 week
-10.79%
1 month
-10.71%
1 year
74.58%
YTD
35.41%
QTD
-7.28%
Financial performance
How have Keros Therapeutics's revenue and profit performed over time
Revenue
$651,000
Gross profit
$651,000
Operating income
-$204.03M
Net income
-$181.57M
Gross margin
100%
Net margin
-27,890.9%
The revenue has surged by 140% since the previous quarter
The gross profit has soared by 140% from the previous quarter
The operating margin has surged by 98% year-on-year and by 55% since the previous quarter
The net margin has soared by 98% YoY and by 55% from the previous quarter
Growth
What is Keros Therapeutics's growth rate over time
Valuation
What is Keros Therapeutics stock price valuation
P/E
N/A
P/B
3.79
P/S
3,108.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,562.32
KROS's EPS is down by 5% year-on-year
KROS's equity has surged by 80% year-on-year and by 27% since the previous quarter
The price to book (P/B) is 16% lower than the 5-year quarterly average of 4.5 and 10% lower than the last 4 quarters average of 4.2
The revenue has surged by 140% since the previous quarter
KROS's P/S is 54% below its last 4 quarters average of 6822.7
Efficiency
How efficient is Keros Therapeutics business performance
KROS's return on sales has surged by 98% year-on-year and by 55% since the previous quarter
The ROE has grown by 8% YoY and by 7% from the previous quarter
The company's return on assets rose by 7% YoY and by 7% QoQ
The ROIC has contracted by 6% from the previous quarter and by 6% YoY
Dividends
What is KROS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KROS.
Financial health
How did Keros Therapeutics financials performed over time
KROS's total assets has soared by 78% YoY and by 27% QoQ
The total liabilities has surged by 53% year-on-year and by 36% since the previous quarter
The debt is 96% less than the equity
KROS's equity has surged by 80% year-on-year and by 27% since the previous quarter
The debt has grown by 38% from the previous quarter and by 35% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.